Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry
DOI:
https://doi.org/10.2340/actadv.v104.19454Keywords:
Atopic dermatitis, Hand eczema, Abrocitinib, JAK-inhibitor, Daily practiceAbstract
Limited daily practice data on the effect of abrocitinib in patients with atopic dermatitis are available. The aim of this multicentre prospective study is to evaluate the effectiveness and safety of abrocitinib in patients with atopic dermatitis treated in daily practice. In a subgroup, the effectiveness of abrocitinib on hand eczema was evaluated. A total of 103 patients from the BioDay registry were included in the study: week 4 (n = 95), week 16 (n = 61) and week 28 (n = 39). At week 28, the Eczema Area and Severity Index (EASI)-50/75/90 was achieved by 81.8%, 57.6%, and 18.2%, respectively, and the weekly average pruritus numerical rating scale ≤ 4 by 62.9%. The effectiveness of abrocitinib was not significantly different between dupilumab non-responders and dupilumab-naïve patients/responders, and between upadacitinib non-responders and upadacitinib-naïve patients/responders. Mean ± standard deviation Hand Eczema Severity Index decreased from 27.4 ± 27.7 at baseline to 7.7 ± 12.1 at week 28 (n = 31). Thirty-two patients (31.1%) discontinued treatment due to ineffectiveness (n = 17), adverse events (n = 9) or both (n = 3). The most frequently reported adverse event was nausea (n = 28). In conclusion, abrocitinib is an effective treatment for atopic dermatitis and can be effective for patients with previous inadequate response to dupilumab or upadacitinib. Furthermore, hand eczema can improve in patients treated with abrocitinib for atopic dermatitis.
Downloads
References
Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 2014; 70: 338-351.
https://doi.org/10.1016/j.jaad.2013.10.010 DOI: https://doi.org/10.1016/j.jaad.2013.10.010
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336-349.
https://doi.org/10.1016/j.jaci.2016.06.010 DOI: https://doi.org/10.1016/j.jaci.2016.06.010
Simpson EL, Thompson MM, Hanifin JM. Prevalence and morphology of hand eczema in patients with atopic dermatitis. Dermatitis 2006; 17: 123-127.
https://doi.org/10.2310/6620.2006.06005 DOI: https://doi.org/10.2310/6620.2006.06005
Thyssen JP, Schuttelaar MLA, Alfonso JH, Andersen KE, Angelova-Fischer I, Arents BWM, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis 2022; 86: 357-378.
https://doi.org/10.1111/cod.14035 DOI: https://doi.org/10.1111/cod.14035
Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Oral Janus kinase inhibitors for atopic dermatitis. Ann Allergy Asthma Immunol 2023; 130: 577-592.
https://doi.org/10.1016/j.anai.2023.01.020 DOI: https://doi.org/10.1016/j.anai.2023.01.020
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis: results from JADE MONO-1, a randomized, phase 3 clinical trial. Lancet 2020; 396: 255-266.
https://doi.org/10.1016/S0140-6736(20)30732-7 DOI: https://doi.org/10.1016/S0140-6736(20)30732-7
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized phase 3 clinical trial. JAMA Dermatol 2020; 156: 863-873.
https://doi.org/10.1001/jamadermatol.2020.1406 DOI: https://doi.org/10.1001/jamadermatol.2020.1406
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol 2022; 86: 104-112.
https://doi.org/10.1016/j.jaad.2021.05.075 DOI: https://doi.org/10.1016/j.jaad.2021.05.075
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med 2021; 384: 1101-1112.
https://doi.org/10.1056/NEJMoa2019380 DOI: https://doi.org/10.1056/NEJMoa2019380
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, multicentre phase 3 trial. Lancet 2022; 400: 273-282.
https://doi.org/10.1016/S0140-6736(22)01199-0 DOI: https://doi.org/10.1016/S0140-6736(22)01199-0
Tong Z, Zhang Y, Zhou K, Zou Y, Wu Z, Chen J, et al. An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab. J Am Acad Dermatol 2023; 89: 826-828.
https://doi.org/10.1016/j.jaad.2023.05.077 DOI: https://doi.org/10.1016/j.jaad.2023.05.077
Olydam JI, Schlösser AR, Custurone P, Nijsten TEC, Hijnen D. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis. J Eur Acad Dermatol Venereol 2023; 37: 2537-2542.
https://doi.org/10.1111/jdv.19378 DOI: https://doi.org/10.1111/jdv.19378
Sitaru S, Preis S, Eberlein B. Successful treatment of atopic hand and foot eczema with oral janus kinase 1 inhibition. Dermatitis 2023; 34: 560.
https://doi.org/10.1089/derm.2022.0030 DOI: https://doi.org/10.1089/derm.2022.0030
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
https://doi.org/10.1034/j.1600-0625.2001.100102.x DOI: https://doi.org/10.1034/j.1600-0625.2001.100102.x
Futamara M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. JAAD 2016; 74: 288-294.
https://doi.org/10.1016/j.jaad.2015.09.062 DOI: https://doi.org/10.1016/j.jaad.2015.09.062
De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402.
https://doi.org/10.2340/00015555-3751 DOI: https://doi.org/10.2340/00015555-3751
Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, et al. Optimizing the management of atopic dermatitis with a new minimal disease activity concept and criteria and consensus-based recommendations for systemic therapy. Br J Dermatol 2023; 188: ljac140.022.
https://doi.org/10.1093/bjd/ljac140.022 DOI: https://doi.org/10.1093/bjd/ljac140.022
Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, et al. Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry. Br J Dermatol 2023; 189: 327-335.
https://doi.org/10.1093/bjd/ljad159 DOI: https://doi.org/10.1093/bjd/ljad159
Beck LA, Deleuran M, Bisonette R, de Bruin-Weller M, Galus R, Nakahara T, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2022; 23: 393-408.
https://doi.org/10.1007/s40257-022-00685-0 DOI: https://doi.org/10.1007/s40257-022-00685-0
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012; 92: 502-507.
https://doi.org/10.2340/00015555-1246 DOI: https://doi.org/10.2340/00015555-1246
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.
https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-206.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Pariser DM, Simpson EL, Gadkari A, Bieber T, Margolis DJ, Brown M, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin 2020; 36: 367-376.
https://doi.org/10.1080/03007995.2019.1699516 DOI: https://doi.org/10.1080/03007995.2019.1699516
Griffiths C, de Bruin-Weller M, Deleuran M, Fargnoli MC, Staumont-Sallé D, Hong CH, et al. Dupilumab in adults with moderate-to-severe atopic dermatitis and prior use of systemic non-steroidal immunosuppressants: analysis of four phase 3 trials. Dermatol Ther (Heidelb) 2021; 11: 1357-1372.
https://doi.org/10.1007/s13555-021-00558-0 DOI: https://doi.org/10.1007/s13555-021-00558-0
Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol 2005; 152: 302-307.
https://doi.org/10.1111/j.1365-2133.2004.06305.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06305.x
Coenraads PJ, Van Der Walle H, Thestrup-Pedersen K, Ruzicka T, Dreno B, De La Loge C, et al. Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol 2005; 152: 296-301.
https://doi.org/10.1111/j.1365-2133.2004.06270.x DOI: https://doi.org/10.1111/j.1365-2133.2004.06270.x
Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087-1091.
https://doi.org/10.1016/j.jclinepi.2006.01.014 DOI: https://doi.org/10.1016/j.jclinepi.2006.01.014
Robitzsch A, Grund S. Miceadds: Some additional multiple imputation functions, especially for 'mice'. R package version 3.13-1. 2022. [accessed 2023 June 20]. Available from: https://cran.r-project.org/web/packages/miceadds/index.html
Boesjes CM, Van der Gang LF, Zuithoff NPA, Bakker DS, Spekhorst LS, Haeck I, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and/or baricitinib: results from the BioDay Registry. Acta Derm Venereol 2023; 103: adv00872.
https://doi.org/10.2340/actadv.v103.5243 DOI: https://doi.org/10.2340/actadv.v103.5243
Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay Registry. Acta Derm Venereol 2022; 102: adv00820.
https://doi.org/10.2340/actadv.v102.3978 DOI: https://doi.org/10.2340/actadv.v102.3978
Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 2018; 179: 54-62.
https://doi.org/10.1111/bjd.16004 DOI: https://doi.org/10.1111/bjd.16004
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2018; 2: 23.
https://doi.org/10.1186/s41927-018-0031-x DOI: https://doi.org/10.1186/s41927-018-0031-x
Silverberg JI, Hong HC, Calimlim BM, Lee WJ, Teixeira HD, Collins EB, et al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol Ther (Heidelb) 2023; 13: 2247-2264.
https://doi.org/10.1007/s13555-023-01000-3 DOI: https://doi.org/10.1007/s13555-023-01000-3
Cheng J, Facheris P, Ungar B, Guttman-Yassky E. Current emerging and investigational drugs for the treatment of chronic hand eczema. Expert Opin Investig Drugs 2022; 31: 843-853.
https://doi.org/10.1080/13543784.2022.2087059 DOI: https://doi.org/10.1080/13543784.2022.2087059
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Esmé Kamphuis, Celeste M. Boesjes, Laura Loman, Marijke Kamsteeg, Inge Haeck, Anneke M.T. van Lynden-van Nes, Klaziena Politiek, Liana F. van der Gang, Marlies de Graaf, Marjolein S. de Bruin-Weller, Marie L.A. Schuttelaar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
